Research graph
References from Gadopiclenol Breast MRI With Half Standard Gadolinium Dose Maintains High Parenchymal Contrast in Intraindividual Comparison. Local targets link to admitted publications; unresolved targets remain external evidence.
Management of women at high risk for breast cancer: new imaging beyond mammography
10.1016/j.breast.2005.08.005 · 2005 · External reference
Contrast-enhanced MRI for breast cancer screening
10.1002/jmri.26654 · 2019 · External reference
Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group
10.1016/j.ejca.2010.02.015 · 2010 · External reference
ACR Appropriateness Criteria® breast cancer screening
10.1016/j.jacr.2017.08.044 · 2017 · External reference
A review of gadolinium-based contrast agents in the setting of repeated MRI for high risk breast cancer screening
10.1016/j.clinimag.2025.110420 · 2025 · External reference
Gadolinium retention in the brain: what do we need to consider for clinical use?
10.1097/rli.0000000000000589 · 2019 · External reference
MRI contrast agents and retention in the brain: review of contemporary knowledge and recommendations to the future
10.1186/s13244-024-01763-z · 2024 · External reference
Gadolinium as a new emerging contaminant of aquatic environments
10.1002/etc.4116 · 2018 · External reference
What do we know about the ecotoxicological implications of the rare earth element gadolinium in aquatic ecosystems?
10.1016/j.scitotenv.2021.146273 · 2021 · External reference
A comprehensive overview of the efficacy and safety of gadopiclenol: a new contrast agent for MRI of the CNS and body
10.1097/rli.0000000000001025 · 2024 · External reference
Clinical safety of gadobutrol: review of over 25 years of use exceeding 100 million administrations
10.1097/rli.0000000000001072 · 2024 · External reference
Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates
10.1148/radiol.2018181151 · 2018 · External reference
Overall gadolinium exposure within the first 5 months after injection of human equivalent doses of gadopiclenol, gadoterate, or gadobutrol in healthy rats
10.1097/rli.0000000000001194 · 2025 · External reference
Physicochemical and pharmacokinetic profiles of gadopiclenol: a new macrocyclic gadolinium chelate with high T1 relaxivity
10.1097/rli.0000000000000563 · 2019 · External reference
Rationales for non-standard GBCA dosing—Low?—High?—When? and Why? A literature-based study
2025 · External reference
Efficacy and safety of gadopiclenol for contrast-enhanced MRI of the central nervous system: the PICTURE randomized clinical trial
10.1097/rli.0000000000000944 · 2023 · External reference
Safety of gadopiclenol after its first year of clinical use
10.1097/rli.0000000000001144 · 2025 · External reference
Dose finding study of gadopiclenol, a new macrocyclic contrast agent, in MRI of central nervous system
10.1097/rli.0000000000000624 · 2020 · External reference
Gadopiclenol enables reduced gadolinium dose while maintaining quality of pulmonary arterial enhancement for pulmonary MRA: an opportunity for improved safety and sustainability
10.1097/rli.0000000000001154 · 2025 · External reference
Efficacy and safety of half-dose gadopiclenol versus full-dose gadobutrol for contrast-enhanced body MRI
10.1148/radiol.222612 · 2023 · External reference
High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer
10.1007/s10549-019-05152-9 · 2019 · External reference
Gadolinium concentration dependent signal enhancement profiles using routine clinical sequences with gadopiclenol, gadoterate, gadobutrol, and gadoxetate at 1.5, 3 and 7 Tesla
10.1016/j.ejrad.2025.112322 · 2025 · External reference
Effects of gadobutrol on background parenchymal enhancement and differential diagnosis between benign and malignant lesions in dynamic magnetic resonance imaging of the breast
10.1007/s12282-021-01229-w · 2021 · External reference
Enhancement of intramammary lymph nodes with lymphoid hyperplasia: a potential pitfall in breast MRI
10.1007/s003300050607 · 1998 · External reference
Gadolinium retention and breast MRI screening: more harm than good?
10.2214/ajr.19.21988 · 2020 · External reference
Symptoms associated with gadolinium exposure (SAGE): a suggested term
10.1148/radiol.2021211349 · 2022 · External reference
Use of real-life safety data from international pharmacovigilance databases to assess the importance of symptoms associated with gadolinium exposure
10.1097/rli.0000000000000880 · 2022 · External reference
Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases
10.1148/radiol.2502080498 · 2009 · External reference
Environmental sustainability and MRI: challenges, opportunities, and a call for action
10.1002/jmri.28994 · 2024 · External reference
Artificial contrast: deep learning for reducing gadolinium-based contrast agents in neuroradiology
10.1097/rli.0000000000000963 · 2023 · External reference
